Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacological Inhibition of MDM2 Induces Apoptosis in p53-Mutated Triple-Negative Breast Cancer

26 Jan 2025

Abstract excerpt

Triple-negative breast cancer (TNBC) represents the most aggressive breast carcinoma subtype lacking efficient therapeutic options. A promising approach in cancer treatment is the pharmacological inhibition of murine double minute 2 (MDM2)-p53 interaction inducing apoptosis in p53 wild-type tumors. However, the role of MDM2 in TNBC with primarily mutant p53 is not well understood. We here selected the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer-related Molecular Pathways
Share to Hedgehog Signaling Pathway Studies
Share to Microtubule and mitosis dynamics

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39940844
DOI: 10.3390/ijms26031078

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacological Inhibition of MDM2 Induces Apoptosis in p53-Mutated Triple-Negative Breast CancerPMID 39940844Read ↗

Effects of Mdm2 Inhibitors on Cellular Viability of Breast Cancer Cell Lines HP100, MCF7Semantic proximity Read ↗

Natural Product MDM2 Inhibitors: Anticancer Activity and Mechanisms of ActionSemantic proximity Read ↗

Identification of a new class of natural product MDM2 inhibitor:In vitroandin vivoanti-breast cancer activities and target validationSemantic proximity Read ↗

Targeting the p53–MDM2 interaction to treat cancerSemantic proximity Read ↗

MDM2 in Tumor Biology and Cancer Therapy: A Review of Current Clinical TrialsSemantic proximity Read ↗

Targeting MDM2-p53 interaction for breast cancer therapySemantic proximity Read ↗

Targeting p53–MDM2 interaction by small-molecule inhibitors: learning from MDM2 inhibitors in clinical trialsSemantic proximity Read ↗

MDM2: current research status and prospects of tumor treatmentSemantic proximity Read ↗

Therapeutics Targeting p53-MDM2 Interaction to Induce Cancer Cell DeathSemantic proximity Read ↗

Targeting MDM2-p53 Interaction for Cancer Therapy: Are We There Yet?Semantic proximity Read ↗

Natural products targeting the p53-MDM2 pathway and mutant p53: Recent advances and implications in cancer medicineSemantic proximity Read ↗

Alteration of MDM2 by the Small Molecule YF438 Exerts Antitumor Effects in Triple-Negative Breast CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.